Preferences for health outcomes associated with Group A Streptococcal disease and vaccination

<p>Abstract</p> <p>Background</p> <p>A 26-valent Group A Streptococcus (GAS) vaccine candidate has been developed that may provide protection against pharyngitis, invasive disease and rheumatic fever. However, recommendations for the use of a new vaccine must be informe...

Full description

Bibliographic Details
Main Authors: Gay Charlene, Salomon Joshua A, Lee Grace M, Hammitt James K
Format: Article
Language:English
Published: BMC 2010-03-01
Series:Health and Quality of Life Outcomes
Online Access:http://www.hqlo.com/content/8/1/28
id doaj-d8e24d68ddf04506bd34b3cdb7edc7e8
record_format Article
spelling doaj-d8e24d68ddf04506bd34b3cdb7edc7e82020-11-25T00:21:15ZengBMCHealth and Quality of Life Outcomes1477-75252010-03-01812810.1186/1477-7525-8-28Preferences for health outcomes associated with Group A Streptococcal disease and vaccinationGay CharleneSalomon Joshua ALee Grace MHammitt James K<p>Abstract</p> <p>Background</p> <p>A 26-valent Group A Streptococcus (GAS) vaccine candidate has been developed that may provide protection against pharyngitis, invasive disease and rheumatic fever. However, recommendations for the use of a new vaccine must be informed by a range of considerations, including parents' preferences for different relevant health outcomes. Our objectives were to: (1) describe parent preferences for GAS disease and vaccination using willingness-to-pay (WTP) and time trade-off (TTO) methods; and (2) understand how parents' implied WTP for a quality-adjusted life year (QALY) gained might vary depending on the particular health outcome considered (e.g. averted GAS disease vs. vaccine adverse events).</p> <p>Methods</p> <p>Telephone interviews were conducted with parents of children diagnosed with GAS pharyngitis at 2 pediatric practice sites in the Boston metropolitan area. WTP and TTO (trading parental longevity for child's health) questions for 2 vaccine and 4 disease-associated health states were asked using a randomly selected opening bid, followed by a 2<sup>nd </sup>bid and a final open-ended question about the amount willing to pay or trade. Descriptive analyses included medians and interquartile ranges for WTP and TTO estimates. The Wilcoxon signed-rank test was used to assess differences in WTP/QALY values for vaccine adverse events vs. disease states.</p> <p>Results</p> <p>Of 119 respondents, 100 (84%) and 96 (81%) provided a complete set of responses for WTP and TTO questions, respectively. The median WTP and discounted (at 3% per year) TTO values to avoid each health state were as follows: local reaction, $30, 0.12 days; systemic reaction, $50, 0.22 days; impetigo, $75, 1.25 days; strep throat, $75, 2.5 days; septic arthritis, $1,000, 6.6 days; and toxic shock syndrome, $3,000, 31.0 days. The median WTP/QALY was significantly higher for vaccine adverse events (~$60,000/QALY) compared to disease states ($18,000 to $36,000/QALY).</p> <p>Conclusions</p> <p>Parents strongly prefer to prevent GAS disease in children compared to vaccine adverse events. However, implied WTP/QALY ratios were higher for the prevention of vaccine adverse events. Regret for errors of commission vs. omission may differ and should be considered by vaccine policymakers.</p> http://www.hqlo.com/content/8/1/28
collection DOAJ
language English
format Article
sources DOAJ
author Gay Charlene
Salomon Joshua A
Lee Grace M
Hammitt James K
spellingShingle Gay Charlene
Salomon Joshua A
Lee Grace M
Hammitt James K
Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
Health and Quality of Life Outcomes
author_facet Gay Charlene
Salomon Joshua A
Lee Grace M
Hammitt James K
author_sort Gay Charlene
title Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_short Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_full Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_fullStr Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_full_unstemmed Preferences for health outcomes associated with Group A Streptococcal disease and vaccination
title_sort preferences for health outcomes associated with group a streptococcal disease and vaccination
publisher BMC
series Health and Quality of Life Outcomes
issn 1477-7525
publishDate 2010-03-01
description <p>Abstract</p> <p>Background</p> <p>A 26-valent Group A Streptococcus (GAS) vaccine candidate has been developed that may provide protection against pharyngitis, invasive disease and rheumatic fever. However, recommendations for the use of a new vaccine must be informed by a range of considerations, including parents' preferences for different relevant health outcomes. Our objectives were to: (1) describe parent preferences for GAS disease and vaccination using willingness-to-pay (WTP) and time trade-off (TTO) methods; and (2) understand how parents' implied WTP for a quality-adjusted life year (QALY) gained might vary depending on the particular health outcome considered (e.g. averted GAS disease vs. vaccine adverse events).</p> <p>Methods</p> <p>Telephone interviews were conducted with parents of children diagnosed with GAS pharyngitis at 2 pediatric practice sites in the Boston metropolitan area. WTP and TTO (trading parental longevity for child's health) questions for 2 vaccine and 4 disease-associated health states were asked using a randomly selected opening bid, followed by a 2<sup>nd </sup>bid and a final open-ended question about the amount willing to pay or trade. Descriptive analyses included medians and interquartile ranges for WTP and TTO estimates. The Wilcoxon signed-rank test was used to assess differences in WTP/QALY values for vaccine adverse events vs. disease states.</p> <p>Results</p> <p>Of 119 respondents, 100 (84%) and 96 (81%) provided a complete set of responses for WTP and TTO questions, respectively. The median WTP and discounted (at 3% per year) TTO values to avoid each health state were as follows: local reaction, $30, 0.12 days; systemic reaction, $50, 0.22 days; impetigo, $75, 1.25 days; strep throat, $75, 2.5 days; septic arthritis, $1,000, 6.6 days; and toxic shock syndrome, $3,000, 31.0 days. The median WTP/QALY was significantly higher for vaccine adverse events (~$60,000/QALY) compared to disease states ($18,000 to $36,000/QALY).</p> <p>Conclusions</p> <p>Parents strongly prefer to prevent GAS disease in children compared to vaccine adverse events. However, implied WTP/QALY ratios were higher for the prevention of vaccine adverse events. Regret for errors of commission vs. omission may differ and should be considered by vaccine policymakers.</p>
url http://www.hqlo.com/content/8/1/28
work_keys_str_mv AT gaycharlene preferencesforhealthoutcomesassociatedwithgroupastreptococcaldiseaseandvaccination
AT salomonjoshuaa preferencesforhealthoutcomesassociatedwithgroupastreptococcaldiseaseandvaccination
AT leegracem preferencesforhealthoutcomesassociatedwithgroupastreptococcaldiseaseandvaccination
AT hammittjamesk preferencesforhealthoutcomesassociatedwithgroupastreptococcaldiseaseandvaccination
_version_ 1725363112754806784